Michael McElhaugh
Directeur Général chez ARBUTUS BIOPHARMA CORPORATION
Fortune : 4 M $ au 30/04/2024
Postes actifs de Michael McElhaugh
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| ARBUTUS BIOPHARMA CORPORATION | Directeur/Membre du Conseil | 01/01/2024 | - |
| Directeur Général | 01/01/2024 | - | |
| Directeur des opérations | 01/11/2022 | - | |
| President | 01/01/2024 | - | |
| Corporate Officer/Principal | 01/12/2018 | 01/11/2022 | |
Arbutus Biopharma, Inc.
 Arbutus Biopharma, Inc. BiotechnologyHealth Technology Arbutus Biopharma, Inc. engages in the research and development of pharmaceutical products for Hepatitis B. Its operation includes covalently closed circular DNA, Capsid Assembly, Cyclophilins, and Surface Antigen. The company was founded by Patrick T. Higgins, Michael J. Sofia, Michael J. McElhaugh, and Bryce A. Roberts in May 2012 and is headquartered in Doylestown, PA. | Directeur Général | 01/01/2024 | - |
| President | 01/01/2024 | - |
Historique de carrière de Michael McElhaugh
Anciens postes connus de Michael McElhaugh
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
Pharmasset, Inc.
 Pharmasset, Inc. Pharmaceuticals: OtherHealth Technology Pharmasset, Inc. developed drugs to treat viral infections. It focued in the development of oral therapeutics for the treatment of hepatitis C virus (HCV) infection. The company was founded in 1998 and was headquartered in Princeton, NJ. | Corporate Officer/Principal | 01/09/2008 | 01/03/2012 |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | - | - |
Arbutus Biopharma, Inc.
Arbutus Biopharma, Inc. BiotechnologyHealth Technology Arbutus Biopharma, Inc. engages in the research and development of pharmaceutical products for Hepatitis B. Its operation includes covalently closed circular DNA, Capsid Assembly, Cyclophilins, and Surface Antigen. The company was founded by Patrick T. Higgins, Michael J. Sofia, Michael J. McElhaugh, and Bryce A. Roberts in May 2012 and is headquartered in Doylestown, PA. | Directeur des opérations | 01/05/2012 | - |
| Fondateur | 01/05/2012 | - |
Formation de Michael McElhaugh
| St. Joseph's University | Undergraduate Degree |
| Thomas Jefferson University | Graduate Degree |
| Johnson Graduate School of Management | Masters Business Admin |
Statistiques
Internationale
| Etats-Unis | 8 |
Opérationnelle
| Corporate Officer/Principal | 3 |
| Chief Operating Officer | 2 |
| Chief Executive Officer | 2 |
Sectorielle
| Health Technology | 5 |
| Consumer Services | 4 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| ARBUTUS BIOPHARMA CORPORATION | Health Technology |
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| Entreprise privées | 2 |
|---|---|
Arbutus Biopharma, Inc.
Arbutus Biopharma, Inc. BiotechnologyHealth Technology Arbutus Biopharma, Inc. engages in the research and development of pharmaceutical products for Hepatitis B. Its operation includes covalently closed circular DNA, Capsid Assembly, Cyclophilins, and Surface Antigen. The company was founded by Patrick T. Higgins, Michael J. Sofia, Michael J. McElhaugh, and Bryce A. Roberts in May 2012 and is headquartered in Doylestown, PA. | Health Technology |
Pharmasset, Inc.
Pharmasset, Inc. Pharmaceuticals: OtherHealth Technology Pharmasset, Inc. developed drugs to treat viral infections. It focued in the development of oral therapeutics for the treatment of hepatitis C virus (HCV) infection. The company was founded in 1998 and was headquartered in Princeton, NJ. | Health Technology |
- Bourse
- Insiders
- Michael McElhaugh
- Expérience
